A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.
PURPOSE: Tumor hypoxia is associated with a poor prognosis, hypoxia modification improves outcome, and hypoxic status predicts benefit from treatment. Yet, there is no universal measure of clinical hypoxia. The aim of this study was to investigate whether a 26-gene hypoxia signature predicted benefi...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2013
|
| _version_ | 1826288191366234112 |
|---|---|
| author | Eustace, A Mani, N Span, P Irlam, J Taylor, J Betts, G Denley, H Miller, C Homer, J Rojas, A Hoskin, P Buffa, F Harris, A Kaanders, J West, C |
| author_facet | Eustace, A Mani, N Span, P Irlam, J Taylor, J Betts, G Denley, H Miller, C Homer, J Rojas, A Hoskin, P Buffa, F Harris, A Kaanders, J West, C |
| author_sort | Eustace, A |
| collection | OXFORD |
| description | PURPOSE: Tumor hypoxia is associated with a poor prognosis, hypoxia modification improves outcome, and hypoxic status predicts benefit from treatment. Yet, there is no universal measure of clinical hypoxia. The aim of this study was to investigate whether a 26-gene hypoxia signature predicted benefit from hypoxia-modifying treatment in both cancer types. EXPERIMENTAL DESIGN: Samples were available from 157 T2-T4 laryngeal cancer and 185 T1-T4a bladder cancer patients enrolled on the accelerated radiotherapy with carbogen and nicotinamide (ARCON) and bladder carbogen nicotinamide (BCON) phase III randomized trials of radiotherapy alone or with carbogen and nicotinamide (CON) respectively. Customized TaqMan low density arrays (TLDA) were used to assess expression of the 26-gene signature using quantitative real-time PCR. The median expression of the 26 genes was used to derive a hypoxia score (HS). Patients were categorized as TLDA-HS low (≤median) or TLDA-HS high (>median). The primary outcome measures were regional control (RC; ARCON) and overall survival (BCON). RESULTS: Laryngeal tumors categorized as TLDA-HS high showed greater benefit from ARCON than TLDA-HS low tumors. Five-year RC was 81% (radiotherapy alone) versus 100% (CON) for TLDA-HS high (P=0.009). For TLDA-HS low, 5-year RC was 91% (radiotherapy alone) versus 90% (CON; P=0.90). TLDA-HS did not predict benefit from CON in bladder cancer. CONCLUSION: The 26-gene hypoxia signature predicts benefit from hypoxia-modifying treatment in laryngeal cancer. These findings will be evaluated in a prospective clinical trial. |
| first_indexed | 2024-03-07T02:09:59Z |
| format | Journal article |
| id | oxford-uuid:a04c0a22-fc82-49f1-bd45-1e657657219c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:09:59Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:a04c0a22-fc82-49f1-bd45-1e657657219c2022-03-27T02:04:25ZA 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a04c0a22-fc82-49f1-bd45-1e657657219cEnglishSymplectic Elements at Oxford2013Eustace, AMani, NSpan, PIrlam, JTaylor, JBetts, GDenley, HMiller, CHomer, JRojas, AHoskin, PBuffa, FHarris, AKaanders, JWest, CPURPOSE: Tumor hypoxia is associated with a poor prognosis, hypoxia modification improves outcome, and hypoxic status predicts benefit from treatment. Yet, there is no universal measure of clinical hypoxia. The aim of this study was to investigate whether a 26-gene hypoxia signature predicted benefit from hypoxia-modifying treatment in both cancer types. EXPERIMENTAL DESIGN: Samples were available from 157 T2-T4 laryngeal cancer and 185 T1-T4a bladder cancer patients enrolled on the accelerated radiotherapy with carbogen and nicotinamide (ARCON) and bladder carbogen nicotinamide (BCON) phase III randomized trials of radiotherapy alone or with carbogen and nicotinamide (CON) respectively. Customized TaqMan low density arrays (TLDA) were used to assess expression of the 26-gene signature using quantitative real-time PCR. The median expression of the 26 genes was used to derive a hypoxia score (HS). Patients were categorized as TLDA-HS low (≤median) or TLDA-HS high (>median). The primary outcome measures were regional control (RC; ARCON) and overall survival (BCON). RESULTS: Laryngeal tumors categorized as TLDA-HS high showed greater benefit from ARCON than TLDA-HS low tumors. Five-year RC was 81% (radiotherapy alone) versus 100% (CON) for TLDA-HS high (P=0.009). For TLDA-HS low, 5-year RC was 91% (radiotherapy alone) versus 90% (CON; P=0.90). TLDA-HS did not predict benefit from CON in bladder cancer. CONCLUSION: The 26-gene hypoxia signature predicts benefit from hypoxia-modifying treatment in laryngeal cancer. These findings will be evaluated in a prospective clinical trial. |
| spellingShingle | Eustace, A Mani, N Span, P Irlam, J Taylor, J Betts, G Denley, H Miller, C Homer, J Rojas, A Hoskin, P Buffa, F Harris, A Kaanders, J West, C A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. |
| title | A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. |
| title_full | A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. |
| title_fullStr | A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. |
| title_full_unstemmed | A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. |
| title_short | A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. |
| title_sort | 26 gene hypoxia signature predicts benefit from hypoxia modifying therapy in laryngeal cancer but not bladder cancer |
| work_keys_str_mv | AT eustacea a26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT manin a26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT spanp a26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT irlamj a26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT taylorj a26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT bettsg a26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT denleyh a26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT millerc a26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT homerj a26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT rojasa a26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT hoskinp a26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT buffaf a26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT harrisa a26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT kaandersj a26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT westc a26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT eustacea 26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT manin 26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT spanp 26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT irlamj 26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT taylorj 26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT bettsg 26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT denleyh 26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT millerc 26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT homerj 26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT rojasa 26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT hoskinp 26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT buffaf 26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT harrisa 26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT kaandersj 26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer AT westc 26genehypoxiasignaturepredictsbenefitfromhypoxiamodifyingtherapyinlaryngealcancerbutnotbladdercancer |